Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis : Infliximab Versus Adalimumab

Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives. Methods: This retrospective single-center study included 33 patients who were treated with anti-tumor necrosis factor (TNF) agents (16 with IFX and 17 with ADA). Patients had diverse etiologies, including juvenile idiopathic arthritis, idiopathic uveitis, and Behçet's disease. Demographic characteristics, systemic diagnosis, findings of the ophthalmological examination, control of ocular inflammation, response to treatment, and the rate of clinical remission were studied. Results: Fourteen (87.5%) patients receiving IFX and 10 (58.8%) patients receiving ADA achieved response to treatment during the follow-up (P = 0.118). The agents were discontinued with complete clinical remission in 6 (37.5%) patients receiving IFX and in 2 (11.8%) patients receiving ADA (P = 0.118). Baseline visual acuities and parameters of inflammation improved significantly in both groups after anti-TNF therapy. Conclusion: Both IFX and ADA are safe and effective for pediatric noninfectious uveitis.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:37

Enthalten in:

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics - 37(2021), 4 vom: 15. Mai, Seite 236-240

Sprache:

Englisch

Beteiligte Personen:

Ucan Gunduz, Gamze [VerfasserIn]
Yalcinbayir, Ozgur [VerfasserIn]
Cekic, Sukru [VerfasserIn]
Yildiz, Meral [VerfasserIn]
Kilic, Sara S [VerfasserIn]

Links:

Volltext

Themen:

Adalimumab
B72HH48FLU
FYS6T7F842
Infliximab
Journal Article
Noninfectious
Pediatric
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
Uveitis

Anmerkungen:

Date Completed 09.11.2021

Date Revised 09.11.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1089/jop.2020.0081

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM320737888